EAM
TBPH icon

EverPoint Asset Management’s Theravance Biopharma TBPH Stock Holding History

EverPoint Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$9.24M Buy
+290,000
New +$9M 0.17% 153

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverPoint Asset Management's TBPH Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in Theravance Biopharma (TBPH) in Q4 2016: 290,000 shares worth $9.24M. The stake represents 0.17% of the portfolio and ranks #153 among its holdings.

98 funds tracked by Wall St. Rank hold TBPH as of Q4 2016.

  • EverPoint Asset Management held 290,000 shares of Theravance Biopharma worth $9.24M as of Q4 2016.
  • Theravance Biopharma was a new EverPoint Asset Management position in Q4 2016.
  • Theravance Biopharma made up 0.17% of EverPoint Asset Management's portfolio in Q4 2016, its #153 holding.
  • 98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.